+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Immune Checkpoint Inhibitors Market by Type and Application - Global Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4656190
  • Report
  • September 2018
  • Region: Global
  • 149 pages
  • Allied Analytics LLP
1 of 4

The global market was valued at $10,566 million in 2017, and is projected to reach $56,530 million by 2025, registering a CAGR of 20.1% from 2018 to 2025.

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumour cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1). Immune checkpoint inhibitors have witnessed increasing demand, owing to increase in the incidence of different forms of cancer, a surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of pipeline drugs, and upsurge in the adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer drive the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.

The global immune checkpoint inhibitor market is segmented based on type, application, and region. On the basis of type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The applications covered in the study include lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Type

  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor

By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin Lymphoma
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
  • Rest of Asia-Pacific
    • LAMEA
    • Brazil
    • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company (ARMO Biosciences)
  • Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  • Immutep Limited
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono, Inc.)
  • Novartis AG
  • Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Incyte Corporation
  • NewLink Genetics
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in incidence of cancer across the globe
3.3.1.2. Surge in global geriatric population
3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
3.3.1.4. Surge in healthcare expenditure worldwide
3.3.2. Restraint
3.3.2.1. Higher cost of immune checkpoint inhibitors
3.3.3. Opportunities
3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in the emerging markets
3.3.4. Impact analyses
3.4. Clinical trials
3.5. Pipeline analyses

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. CTLA-4 inhibitor
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3. PD-1 inhibitor
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. PD-L1 inhibitor
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung cancer
5.2.1. Market size and forecast
5.3. Bladder cancer
5.3.1. Market size and forecast
5.4. Melanoma
5.4.1. Market size and forecast
5.5. Hodgkin lymphoma
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.2. Canada
6.2.2.3. Mexico
6.2.3. North America market size and forecast, by type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.2. France
6.3.2.3. UK
6.3.2.4. Rest of Europe
6.3.3. Europe market size and forecast, by type
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Australia
6.4.2.4. India
6.4.2.5. Rest of Asia-Pacific
6.4.3. Asia-Pacific market size and forecast, by type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.2. Rest of LAMEA
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Bristol-Myers Squibb Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Eli Lilly and Company (ARMO BioSciences)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Immutep Limited
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. Merck & Co., Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Merck KGaA (EMD Serono, Inc.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6 Key strategic moves and development
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Immune Checkpoint Inhibitors Market, by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018-2025, the global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is expected to reach $65,427 million by 2025, growing at a CAGR of 25.6% from 2018 to 2025.

Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells. Immune checkpoint inhibitors are expected to exhibit significant market growth during the forecast period, due to upsurge in demand for ideal therapeutics for the treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and surge in prevalence of cancer across the globe.

Based on type, the global immune checkpoint inhibitors market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The PD-1 inhibitor segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. However, PD-L1 inhibitor segment is projected to exhibit the fastest growth during the forecast period, owing to rise in use of durvalumab & avelumab and surge in R&D for combination studies of PD-L1 inhibitors for newer indications.

By application, the market is classified into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due to increase in use of immune check point inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due to increase in incidence of bladder cancer.

Key Findings of the Immune Checkpoint Inhibitors Market:

Based on type, the PD-L1 inhibitor segment is expected to experience rapid growth, registering a CAGR of 28.6% from 2018 to 2025.
Depending on application, the lung cancer segment held nearly half of the global market share in 2017, and is expected to remain dominant throughout the forecast period.
Region wise, Asia-Pacific is estimated to grow at a CAGR of 27.7% during the forecast period.

North America accounted for more than one-half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This is attributed to increase in demand for immune checkpoint inhibitors, high prevalence of cancer, rise in number of trained medical professionals, and supportive reimbursement policies in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to upsurge in prevalence of cancer coupled with increase in adoption of immune checkpoint inhibitors.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll